RNAZ - transcodetherapeutics.com Operating profit before deduction of amortization
TransCode Therapeutics (RNAZ) aims for the global implementation of RNA delivery systems to combat metastases, while building a vast array of patents and partnerships through innovative cancer cell penetration methods. Absolute EBITDA visualizes the financial trend, where the 0.00 metric reflects current dynamics. The final outcome depends on clinical trial results and strict capital management in the absence of profit.
TransCode Therapeutics, Inc. - analytical breakdowns and key metrics (RNAZ)
- stock value and consensus price forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- debt level and financial liquidity data:
Debt to Capital TransCode Therapeutics|RNAZ - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital TransCode Therapeutics Inc.|RNAZ - Company Total Debt|Debt to Book Capital TransCode Therapeutics|RNAZ - Company Long-Term Debts|Company Short-Term Loans and Borrowings TransCode Therapeutics|Immediate Liquidity transcodetherapeutics.com
- earnings and market multiples details:
RNAZ - Company Net Income|Expected Net Income TransCode Therapeutics|RNAZ - P/E Multiple|Forward P/E Multiple TransCode Therapeutics Inc.|RNAZ - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio TransCode Therapeutics|RNAZ - Operating profit EBITDA|Net earnings per one share for the last twelve months TransCode Therapeutics|RNAZ - Net earnings per share for the last 12 months|Quarterly EPS earnings growth transcodetherapeutics.com|RNAZ - Net earnings per share growth this year|Projected earnings per share increase next year TransCode Therapeutics
Fundamental company valuation:TransCode Therapeutics RNAZ
This indicator captures actual cash flows from core operations before accounting for tax and interest obligations, allowing for the identification of hidden cyclicality in cash inflows. Analyzing the EBITDA chronology on the GURU.Markets platform helps assess the sustainability of the model: for TransCode Therapeutics (RNAZ), the absence of sales turns this metric into a reflection of rising costs for preclinical research of RNA drugs, eliminating the influence of operating leverage.
Who TransCode Therapeutics competes with
Operating income before deduction of amortization Tempus (TEM)|Qiagen N.V. - Operating profit EBITDA|ionispharma.com (IONS) - Operating profit before deduction of amortization|Repligen (RGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Avidity Biosciences Inc (RNA)|CRSP (CRISPR Therapeutics Corp) - Operating profit EBITDA|Operating profit before amortization WGS (GeneDx Corp)|Operating profit EBITDA RARE|BEAM - Profit before interest, taxes and amortization|Sarepta - Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization TWST|TXG: Operating profit before deduction of amortization|Intellia Corp - Company profit before taxes, interest and amortization|STOK: Operating profit EBITDA|biolifesolutions.com - Income before deduction of interest, taxes and amortization|WVE (Wave Life Sciences Ltd.) - Operating profit EBITDA|Profit before interest, taxes and amortization Maze Therapeutics, Inc. MAZE|Profit before payment of interest, taxes and amortization Sionna Pharma (SION)|PRME (Prime Medicine Bio) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA TSHA (Taysha Gene Therapies)|Operating profit EBITDA uniqure.com QURE|MGTX - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization RGNX|SLDB: Operating profit EBITDA|Profit before interest, taxes and amortization Ocugen Pharma (OCGN)|Operating profit before deduction of amortization PACB|Operating profit EBITDA benitec.com|Operating profit before deduction of amortization DSGN (Design Therapeutics, Inc.)|Company profit before taxes, interest and amortization RCKT|Operating profit EBITDA FDMT (4D Molecular Therapeutics Inc)|Operating income before deduction of amortization Lexeo Therapeutics Inc. (LXEO)|Korro Bio, Inc - Operating profit EBITDA|editasmedicine.com (EDIT) - Operating profit before deduction of amortization|Silence Therapeutics plc (SLN) - Profit before payment of interest, taxes and amortization|PRQR - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization Codexis Inc|SGMO: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Nautilus Biotechnology (NAUT)|metagenomi.co - Operating profit before amortization|Operating profit EBITDA DTIL (Precision BioSciences, Inc.)|Operating profit EBITDA Generation Bio Co GBIO|BOLD: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization XCUR|IMNN: Operating profit EBITDA|Operating profit before amortization PHIO|Profit before payment of interest, taxes and amortization Mustang Bio Inc|Operating profit before amortization BNGO (Bionano)|Operating profit EBITDA APDN|Operating profit EBITDA bluebird bio, Inc (BLUE)|ImmunoPrecise Antibodies Ltd. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization OMGA (omegatherapeutics.com)|OMIC - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization RGLS (Regulus Therapeutics, Inc.)|SYRS: Operating profit EBITDA|Telesis Bio, Inc (TBIO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization TRACON Pharmaceuticals|Operating profit before amortization UBX (unitybiotechnology.com)
